TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Carfilzomib, Rituximab and Dexamethasone in Waldenstrom's Macroglobulinemia

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of Waldenstrom's Macroglobulinemia~* Symptomatic disease~* Measurable disease~* Life expectancy of greater than 12 weeks~* Adequate organ and marrow function~* CD20 positive based on any previous performed bone marrow immunohistochemistry or flow cytometric analysis~* Disease free of prior malignancies for \>/= 5 years with the exception of currently treated basal cell, squamous cell carcinoma of the skin, or carcinoma in situ of the cervix or breast~Exclusion Criteria:~* More than one prior therapy~* Previous therapy with a proteasome inhibitor or rituximab~* Chemotherapy or radiotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study or not recovered from adverse events due to agents administered more than 4 weeks earlier~* Currently receiving treatment for any malignancy~* Major surgery within 21 days prior to study entry~* Acute active infection requiring treatment (systemic antibiotics, antivirals, or antifungals) within 14 days prior to study entry~* Uncontrolled hypertension or uncontrolled diabetes~* Significant neuropathy (Grades 3-4, or Grade 2 with pain) within 14 days prior to study entry~* Known history of allergy to Captisol~* Receiving any other study agents~* Known brain metastases~* History of allergic reactions attributed to compounds of similar chemical or biologic composition to carfilzomib, rituximab, and/or dexamethasone~* Contraindication to any of the required concomitant drugs or supportive treatments, including hypersensitivity to all anticoagulation and antiplatelet options, antiviral drugs, or intolerance to hydration due to preexisting pulmonary or cardiac impairment~* Uncontrolled intercurrent illness including, but not limited to ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements~* Pregnant or lactating~* HIV-positive on combination antiretroviral therapy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Treatment Arm (Type: EXPERIMENTAL): Carfilzomib, dexamethasone, rituximab

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Omarigliptin (MK-3102) Clinical Trial - Placebo- and Sitagliptin-Controlled Monotherapy Study in Japanese Patients With Type 2 Diabetes Mellitus (MK-3102-020)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Has type 2 diabetes mellitus~Exclusion Criteria:~* History of type 1 diabetes mellitus or a history of ketoacidosis~* History of any of the following medications: thiazolidinediones and/or insulin within 12 weeks prior to study participation, omarigliptin and/or sitagliptin anytime

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Omarigliptin 25 mg (Phase A+B) (Type: EXPERIMENTAL): Omarigliptin 25 mg once weekly for 52 weeks (Phase A + B)
- Sitagliptin (Phase A) switching to Omarigliptin (Phase B) (Type: ACTIVE_COMPARATOR): Sitagliptin 50 mg once daily for 24 weeks (Phase A) switching to omarigliptin 25 mg once weekly for 28 weeks (Phase B)
- Placebo (Phase A) switching to Omarigliptin (Phase B) (Type: PLACEBO_COMPARATOR): Placebo for 24 weeks (Phase A) switching to omarigliptin 25 mg once weekly for 28 weeks (Phase B)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: DS-8201a in Human Epidermal Growth Factor Receptor 2 (HER2)-Expressing Gastric Cancer [DESTINY-Gastric01]

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~1. Has a pathologically documented locally advanced or metastatic adenocarcinoma of gastric or gastroesophageal junction~2. Progression on and after at least 2 prior regimens~3. Has an adequate tumor sample~4. Has measurable disease based on Response Evaluation Criteria In Solid Tumors (RECIST) version 1.1~Exclusion Criteria:~1. Has a medical history of myocardial infarction, symptomatic congestive heart failure (CHF) (NYHA classes II-IV), unstable angina or serious cardiac arrhythmia~2. Has a QTc prolongation to \> 450 millisecond (ms) in males and \> 470 ms in females~3. Has a medical history of clinically significant lung disease~4. Is suspected to have certain other protocol-defined diseases based on imaging at screening period~5. Has history of any disease, metastatic condition, drug/medication use or other condition that might, per protocol or in the opinion of the investigator, compromise:~   1. safety or well-being of the participant or offspring~  2. safety of study staff~  3. analysis of results

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Parallel: DS-8201a (Type: EXPERIMENTAL): Participants with HER2-overexpressing (IHC 3+ or IHC 2+/ISH+) advanced gastric or gastroesophageal junction adenocarcinoma, whose disease has progressed on two prior regimens, will receive DS-8201a once every 3 weeks.
- Parallel: Physician's Choice (Type: ACTIVE_COMPARATOR): Participants with HER2-overexpressing (IHC 3+ or IHC 2+/ISH+) advanced gastric or gastroesophageal junction adenocarcinoma, whose disease has progressed on two prior regimens, will receive monotherapy prescribed by the physician before enrollment.
- Exploratory: Naïve HER2 IHC 2+/ISH- (Type: OTHER): A maximum of 20 non-randomized participants with HER2 IHC 2+/ISH- advanced gastric or gastroesophageal junction adenocarcinoma will receive DS-8201a once every three weeks.
- Exploratory: Naïve HER2 IHC 1+ (Type: OTHER): A maximum of 20 non-randomized patients with HER2 IHC 1+ advanced gastric or gastroesophageal junction adenocarcinoma will receive DS-8201a once every 3 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Hepatitis B Vaccine in Chronic Hepatitis B Patients With Low Serum HBsAg

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Naïve or treated chronic hepatitis B patients with positive HBsAg and negative HBeAg;~2. Quantitative serum HBsAg (qHBsAg) \<2000 IU/ml;~3. No HIV co-infection;~4. No obvious immunodeficiency (such as renal failure, chemotherapy, radiotherapy, immunosuppressant);~5. Aged 3 to 80 years;~Exclusion Criteria:~1. Pregnancy~2. Allergic to HBV vaccine or yeast.~3. Hepatic decompensation

- Gender: ALL
- Minimum Age: 3 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Engerix-B (Type: EXPERIMENTAL): Engerix-B (20 μg/ml, GlaxoSmithKline) was administered at 0-2-4-6-8-10-12 months in dosage of 40μg for \>20 years old and 20μg for \< or =20 years old

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study Comparing a Fixed-Dose Capsule of Esomeprazole 40mg and LDA 325mg With Free Combination

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Body mass index of 19-29kg/m2, inclusive~* Weight of 50-95kg, inclusive~* Clinically normal physical findings and laboratory values including hepatitis B, hepatitis C, and HIV, as judged by the Investigator~Exclusion Criteria:~* Significant clinical illness within the 2 weeks preceding the first dose of investigational products, as judged by the Investigator~* History of mental, cardiac, renal, hepatitis, neurological, or significant gastrointestinal disease, as judged by the Investigator~* Condition which could modify the absorption of the investigational products, as judged by the Investigator

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 50 Years
- Healthy Volunteers: t

Study Arms:
- 1 (Type: EXPERIMENTAL): combination capsule of Esomeprazole 40mg + ASA 325mg
- 2 (Type: EXPERIMENTAL): Esomeprazole 40 mg capsule and ASA 325 mg tablet

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The Effect of Dexmedetomidine on Hemodynamic Response During Double Lumen Endotracheal Intubation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* ASA Physical Status I-III~* Undergoing Elective Thoracotomy or Thoracoscopy~* Required Left Sided-double Lumen Endotracheal Intubation~Exclusion Criteria:~* Patients with bradycardia (heart rate \< 50 beat per minute) or heart block~* Suspected of Difficult Intubation~* Patients Who Are at Risk for Rapid Change of Hemodynamics~* Allergic to Dexmedetomidine~* Hepatic or Renal Impairment (Preoperative Serum Creatinine \> 1.5 mg/dl)~* Pregnancy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- dexmedetomidine (Type: ACTIVE_COMPARATOR): None
- control (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Biomarker-Guided Fluorouracil in Treating Patients With Colorectal Cancer Receiving Combination Chemotherapy

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically confirmed colorectal cancer~* Patients scheduled to receive mFOLFOX6 (in the adjuvant setting or for metastatic disease) as part of their chemotherapy regimen~PATIENT CHARACTERISTICS:~* ECOG performance status 0-2~* Life expectancy \> 6 months~* ANC ≥ 1,500/mm³~* Platelet count ≥ 100,000/mm³~* Serum creatinine ≤ 1.5 mg/dL~* Total bilirubin ≤ 1.5 times upper limit of normal (ULN)~* AST and ALT ≤ 2.5 times ULN (≤ 5 times ULN in the presence of liver metastases)~* Fertile patients must use effective contraception~* Negative pregnancy test~* Not pregnant or nursing~* No serious concomitant systemic disorders, including active infection that, in the opinion of the investigator, would compromise the patient's safety or ability to complete the study~* No altered mental status precluding understanding of the informed consent process and/or completion of the necessary studies~* Must be able to follow protocol requirements and give informed consent~PRIOR CONCURRENT THERAPY:~* See Disease Characteristics~* Concurrent bevacizumab allowed~* No concurrent warfarin (Coumadin®)~  * Concurrent enoxaparin (Lovenox®) allowed~* No concurrent theophylline or aminophylline~* No chocolate beginning 12 hours before day 1 of each course and through the end of that course's fluorouracil continuous IV

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- mFOLFOX6 (Type: EXPERIMENTAL): Patients will receive cycle 1 of standard dose mFOLFOX6, with the same dose of mFOLFOX6 continued in subsequent cycles, once patient achieves the target AUC.~mFOLFOX 6 is a regimen comprised of Oxaliplatin + Leucovorin +5-Fluorouracil (FU)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Treatment for Alcoholism and Post-Traumatic Stress Disorder (Naltrexone)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: FACTORIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Meets criteria for alcohol dependence and post-traumatic stress disorder.~* Heavy drinking in the past 30 days (an average of more than 12 alcohol drinks per week with at least 1 day of 4 or more drinks).~* Successfully complete medical detoxification.~* Exhibit clinically significant trauma-related symptoms.~* Live in a commutable distance to the University of Pennsylvania and agree to follow-up visits.~* Aged between 18 and 65 years old.~* Able to provide an informed consent.~* Speak and read English.~Exclusion Criteria:~* Current diagnosis of any substance dependence other than alcohol, nicotine, or cannabis.~* Evidence of opiate use in the past 30 days.~* Significant risk of violence or history of serious violent behavior during the past year.~* Continued contact with an intimate partner if assault by the partner is the index trauma.~* Changes in dosage or medication for any SSRI treatment in the three months prior to entering the study.~* Unstable or serious medical illness.~* Current severe psychiatric symptom.~* Mental retardation or another pervasive developmental disorder.~* Use of an investigational medication in the past 30 days.~* Pregnant, nursing or not using reliable contraception.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Naltrexone alone (Type: ACTIVE_COMPARATOR): Naltrexone alone
- Naltrexone with CBT for PTSD (Type: ACTIVE_COMPARATOR): Naltrexone with CBT for PTSD
- Placebo with CBT for PTSD (Type: ACTIVE_COMPARATOR): Placebo with CBT for PTSD
- Placebo alone (Type: PLACEBO_COMPARATOR): Placebo alone

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Open-Label Study Comparing Etanercept to Conventional Disease Modifying Antirheumatic Drug (DMARD) Therapy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of Rheumatoid Arthritis (RA)~* Currently receiving a suboptimal response to a stable dose of methotrexate for treatment of Rheumatoid Arthritis (RA)~* Active Rheumatoid Arthritis (RA) at time of screening and baseline~Exclusion Criteria:~* Previous or current treatment with etanercept, other tumor necrosis factor-alpha inhibitors, or other biologic agents~* Concurrent treatment with a Disease Modifying Antirheumatic Drug (DMARD), other than methotrexate, at screening~* Receipt of any Disease Modifying Antirheumatic Drug (DMARD), other than methotrexate, within 3 months before screening

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 69 Years
- Healthy Volunteers: f

Study Arms:
- Phase 1 Etanercept + methotrexate (Type: EXPERIMENTAL): Phase 1: Etanercept + methotrexate
- Phase 1 Conventional DMARD (SSZ or HCQ) + MTX (Type: ACTIVE_COMPARATOR): Phase 1: Sulfasalazine (SSZ) + methotrexate (MTX) OR Phase 1: Hydrocholoquine (HCQ) + methotrexate

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of Dexmedetomidine on Post-operative Narcotic Requirements and Pain Scores in Bariatric Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients must be undergoing open bariatric surgery at WVUH-ruby hospital. - They must be ASA class 1, 2 and 3.~* Consented individuals.~* They must be between the age of 18 to 55.~Exclusion Criteria:~* History of bradycardia or tachy-brady syndrome HR\<45.~* 1st degree heart block or higher.~* Patient refusal.~* On pain medication for any reason for more than 24 hrs within 2 weeks of procedure.~* Allergy to medication.~* History of alcohol or drug abuse.~* History of Cardiac/ liver/ kidney disease

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: f

Study Arms:
- dexmedetomidine (Type: EXPERIMENTAL): Experimental group will receive 1mcg/kg IV dexmedetomidine over 10 minutes intraoperatively at the beginning of surgical closure
- Normal Saline (Type: ACTIVE_COMPARATOR): Control group will receive Normal saline over 15 minutes at the beginning of surgical closure

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Investigating Hearing Aid Frequency Response Curves 2

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* N3 - N5 Hearing losses~* Healthy Outer ear~* No visible congenital or traumatic deformity of the outer ear~* Symmetrical hearing loss - no air-bone gap greater than 10 dB at all 500, 1000, 2000, and 4000 Hz.~* Ability to answer questions and repeat sentences~* No history of problematic tinnitus or pain/discomfort from loud sounds~* No history of active drainage from the ears in the past 90 days~* Willingness to wear different styles of couplings~* Willingness to wear binaural fitting~* Experienced Users = more than 3 months of hearing aid experience~* Ability to travel to Sonova facilities~Exclusion Criteria:~* Contraindications to the medical device (MD) in this study (e.g. known hypersensitivity or allergy to the investigational products)~* Limited mobility/not able to come to the scheduled visit~* Inability to produce reliable hearing test results~* History of active drainage from the ear in the previous 90 days~* Abnormal appearance of the eardrum and ear canal.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 99 Years
- Healthy Volunteers: t

Study Arms:
- Participants with Hearing Loss (Type: EXPERIMENTAL): Individuals with hearing loss that meet the candidacy to wear hearing aids. All interventions are associated with the fitting of binaural hearing aids with various coupling methods. All participants will be assessed under all interventions.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Ticagrelor vs Clopidogrel Effect on MFR in CAD Population

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Age ≥ 18 years old~2. Stable coronary artery disease on stable medical treatment.~3. BMI equal to or less than 30 kg/m2~4. No clinically significant abnormalities in baseline laboratory work~5. No clinically significant arrhythmias on baseline 12-lead electrocardiogram~6. Female subjects must be post-menopausal, surgically sterilized or have negative urine beta human chorionic gonadotropin pregnancy test at initial screening and maintain effective contraceptive methods throughout the trial and for 7 days following the end of dosing treatment.~Exclusion Criteria:~1. Any contraindication against the use of clopidogrel, ticagrelor and/or ASA.~2. Oral anticoagulation therapy.~3. History of intracranial bleeding.~4. Recent or active pathological bleeding, such as peptic ulcer.~5. Moderate or severe hepatic impairment.~6. History or risk of bradycardia.~7. Known second- or third-degree AV block without pacemaker~8. Dyspnea (NYHA III/IV), wheezing asthma or COPD.~9. Coronary artery bypass graft (CABG) surgery within 90 days prior to screening or at any time after consent.~10. Percutaneous coronary intervention (PCI) within 90 days prior to screening or at any time following consent.~11. Acute myocardial infarction or acute coronary syndrome within 60 days prior to screening or at any time following consent.~12. Any scheduled surgery during the trial period, including dental.~13. Concomitant therapy with strong cytochrome CYP 3A inhibitor or inducer.~14. Recent use of dipyridamole, dipyridamole-containing medications (e.g. Aggrenox)~15. Known hypersensitivity to the investigational drug or any of its components.~16. Known hypersensitivity to adenosine.~17. Lactose intolerance~18. Breastfeeding or pregnancy.~19. Claustrophobia or inability to lie still in a supine position~20. Unwillingness to provide informed consent

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- stable CAD management (Type: EXPERIMENTAL): Experimental: Ticagrelor (BrilintaTM) 90 mg tablet by mouth twice a day
- CAD comparison group (Type: ACTIVE_COMPARATOR): Active comparator: clopidogrel 75 mg plus placebo tablet by mouth twice a day.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete